Invivyd (NASDAQ:IVVD) Shares Gap Up – What’s Next?

by · The Cerbat Gem

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $2.43, but opened at $2.51. Invivyd shares last traded at $2.4350, with a volume of 919,617 shares changing hands.

Analyst Ratings Changes

IVVD has been the subject of a number of research analyst reports. Cantor Fitzgerald started coverage on shares of Invivyd in a research report on Monday, October 6th. They issued an “overweight” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Wednesday. D Boral Capital lowered shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. HC Wainwright upped their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Invivyd has an average rating of “Hold” and a consensus price target of $7.33.

Get Our Latest Stock Analysis on IVVD

Invivyd Stock Performance

The company has a market cap of $595.62 million, a price-to-earnings ratio of -5.41 and a beta of 0.61. The company’s 50 day moving average price is $1.80 and its 200 day moving average price is $1.18.

Invivyd (NASDAQ:IVVD – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, equities research analysts forecast that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Insider Activity at Invivyd

In related news, Director Kevin F. Mclaughlin acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $2.50 per share, with a total value of $125,000.00. Following the purchase, the director owned 50,000 shares of the company’s stock, valued at approximately $125,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 25.40% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. bought a new stake in shares of Invivyd during the 3rd quarter worth $18,831,000. ADAR1 Capital Management LLC bought a new stake in Invivyd during the third quarter valued at about $8,108,000. Vanguard Group Inc. grew its position in shares of Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. 683 Capital Management LLC increased its stake in shares of Invivyd by 2.3% in the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company’s stock worth $2,195,000 after purchasing an additional 70,000 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Invivyd by 15.8% during the 3rd quarter. Millennium Management LLC now owns 1,446,615 shares of the company’s stock worth $1,591,000 after purchasing an additional 197,522 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

Featured Articles